
Simon J Hogg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3913938/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Targeting the epigenetic regulation of antitumour immunity. Nature Reviews Drug Discovery, 2020, 19, 776-800.	46.4	264
2	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Cell Reports, 2017, 18, 2162-2174.	6.4	244
3	Tumor immune evasion arises through loss of TNF sensitivity. Science Immunology, 2018, 3, .	11.9	244
4	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell, 2021, 184, 4032-4047.e31.	28.9	131
5	CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. Leukemia, 2015, 29, 1437-1441.	7.2	120
6	The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. Cell, 2021, 184, 3143-3162.e32.	28.9	103
7	Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Cancer Cell, 2020, 38, 198-211.e8.	16.8	99
8	Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. New England Journal of Medicine, 2022, 386, 735-743.	27.0	87
9	CDK13 cooperates with CDK12 to control global RNA polymerase II processivity. Science Advances, 2020, 6, .	10.3	79
10	Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition. Nature Genetics, 2021, 53, 707-718.	21.4	61
11	Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. Molecular Cell, 2021, 81, 2183-2200.e13.	9.7	59
12	BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. Molecular Cancer Therapeutics, 2016, 15, 2030-2041.	4.1	57
13	The natural function of the malaria parasite's chloroquine resistance transporter. Nature Communications, 2020, 11, 3922.	12.8	53
14	Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD–Driven Acute Myeloid Leukemia. Cancer Discovery, 2021, 11, 1582-1599.	9.4	35
15	The Drug Vehicle and Solvent N-Methylpyrrolidone Is an Immunomodulator and Antimyeloma Compound. Cell Reports, 2014, 7, 1009-1019.	6.4	34
16	The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock. Oncogenesis, 2016, 5, e216-e216.	4.9	24
17	Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML. Cancer Discovery, 2022, 12, 1560-1579.	9.4	13
18	Development of single and mixed isoform selectivity PI3Kδ inhibitors by targeting Asn836 of PI3Kδ. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4790-4794.	2.2	11

SIMON J HOGG

#	Article	IF	CITATIONS
19	Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia. EMBO Molecular Medicine, 2022, 14, e15203.	6.9	10
20	Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma. Leukemia, 2022, 36, 1654-1665.	7.2	9
21	BET Inhibition Enhances TNF-Mediated Antitumor Immunity. Cancer Immunology Research, 2022, 10, 87-107.	3.4	8
22	Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma. Haematologica, 2021, 106, 2013-2017.	3.5	7
23	Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation. Cell Reports, 2020, 33, 108290.	6.4	4
24	Letter to the Editor, "BET Inhibitor JQ1 Blocks Inflammation and Bone Destruction― Journal of Dental Research, 2015, 94, 229-229.	5.2	2
25	<i>ZRSR2</i> Mutation Induced Minor Intron Retention Drives MDS and Diverse Cancer Predisposition Via Aberrant Splicing of <i>LZTR1</i> . Blood, 2020, 136, 10-11.	1.4	1
26	Impaired RAS Proteolysis Drives Clonal Hematopoietic Transformation. Blood, 2021, 138, 356-356.	1.4	0